Breaking News Instant updates and real-time market news.

PFE

Pfizer

$40.72

0.08 (0.20%)

04:55
05/13/19
05/13
04:55
05/13/19
04:55

Pfizer management to meet with FBN Securities

Group Luncheon Meeting to be held in New York, NY on May 13 at 12:00 pm hosted by FBN Securities.

  • 13

    May

  • 14

    May

  • 16

    May

  • 18

    May

  • 31

    May

PFE Pfizer
$40.72

0.08 (0.20%)

02/20/19
02/20/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) resumed with a Neutral from Sell at Citi with analyst Andrew Baum saying the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. 2. Transocean (RIG) and Diamond Offshore (DO) were upgraded to Overweight from Underweight at Barclays. 3. American Axle (AXL) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy citing progress with restructuring, GM's (GM) truck cycle, and balance sheet deleveraging. 4. Credit Suisse (CS) upgraded to Hold from Sell at Berenberg. 5. Ipsen (IPSEY) upgraded to Neutral from Sell at Goldman Sachs with analyst Diana Na citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
LEHM
02/26/19
NO CHANGE
LEHM
Galapagos weakness could be tied to Pfizer safety alert, says Barclays
Barclays believes the weakness today in Galapagos NV (GLPG) could be attributed to, at least in part, the FDA's safety communication on Pfizer's (PFE) post-marketing study of 10mg daily Xeljanz. Competitor safety issues with higher dose JAK inhibitors was a major focus of Galapagos' post-earnings conference call last week, Barclays tells investors in a research note. Galapagos management, while limited in what it can say pending the data, seems to believe they can get both doses approved, Barclays contends. Further, the firm points out that the company has received no communication and sees no reason to conclude that the FDA has determined that thromboembolic events are a class effect of the JAKs. Shares of Galapagos are down 1.5%, or $1.45, to $97.28 in late morning trading.
05/07/19
ROTH
05/07/19
NO CHANGE
Target $51
ROTH
Buy
Eidos Therapeutics raised to $51 from $28 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Eidos Therapeutics (EIDX) to $51 from $28 driven by an increase in AG10's annual price from $150,000 to $225,000 and Probability of Success adjustment from 70% to 80% after Pfizer's (PFE) tafamadis received U.S. approval with a high sticker price of $225,000, two months ahead of schedule. The analyst believes this makes life easier for Eidos Therapeutics to maintain and even expedite enrollment into its Phase 3 ATTRibute-CM trial. Rahimi reiterates a Buy rating on Eidos Therapeutics shares.
05/09/19
BARD
05/09/19
NO CHANGE
BARD
Outperform
Baird names Sarepta a 'Fresh Pick' ahead of Pfizer data
Baird analyst Brian Skorney named Sarepta as a "Fresh Pick" ahead of the report of competitive data due in late June from Pfizer's (PFE) Duchenne muscular dystrophy program that he predicts will "fall flat." If that turns out to be the case, it should remove the most significant overhang on Sarepta shares, contends Skorney, who keeps an Outperform rating on Sarepta.

TODAY'S FREE FLY STORIES

TIF

Tiffany

$84.51

2.27 (2.76%)

07:26
08/22/19
08/22
07:26
08/22/19
07:26
Recommendations
Tiffany analyst commentary  »

Tiffany price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

NVO

Novo Nordisk

$51.82

0.54 (1.05%)

07:26
08/22/19
08/22
07:26
08/22/19
07:26
Hot Stocks
Novo Nordisk says EC grants extension of indication for Fiasp »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 25

    Sep

AZN

AstraZeneca

$45.42

0.8 (1.79%)

07:24
08/22/19
08/22
07:24
08/22/19
07:24
Hot Stocks
AstraZeneca agrees to buy FDA Priority Review Voucher from Sobi for $95M »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 16

    Sep

  • 25

    Sep

  • 02

    Oct

AAPL

Apple

$212.69

2.34 (1.11%)

07:23
08/22/19
08/22
07:23
08/22/19
07:23
Periodicals
Apple plans to launch Pro iPhones with 3-sensor camera systems, Bloomberg says »

Apple is planning to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$45.42

0.8 (1.79%)

, FGEN

FibroGen

$44.90

0.36 (0.81%)

07:23
08/22/19
08/22
07:23
08/22/19
07:23
Hot Stocks
AstraZeneca says Roxadustat approved in China for new anemia indication »

AstraZeneca (AZN)…

AZN

AstraZeneca

$45.42

0.8 (1.79%)

FGEN

FibroGen

$44.90

0.36 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 16

    Sep

  • 25

    Sep

  • 02

    Oct

DK

Delek US

$33.35

0.555 (1.69%)

07:22
08/22/19
08/22
07:22
08/22/19
07:22
Downgrade
Delek US rating change  »

Delek US downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$30.14

4.165 (16.04%)

07:22
08/22/19
08/22
07:22
08/22/19
07:22
Recommendations
Pinduoduo analyst commentary  »

Pinduoduo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WORK

Slack Technologies

$30.81

0.315 (1.03%)

, MSFT

Microsoft

$138.77

1.52 (1.11%)

07:22
08/22/19
08/22
07:22
08/22/19
07:22
Initiation
Slack Technologies, Microsoft initiated  »

Slack Technologies…

WORK

Slack Technologies

$30.81

0.315 (1.03%)

MSFT

Microsoft

$138.77

1.52 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

MSGN

MSG Networks

$14.78

-2.07 (-12.28%)

07:21
08/22/19
08/22
07:21
08/22/19
07:21
Recommendations
MSG Networks analyst commentary  »

MSG Networks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$103.11

17.54 (20.50%)

07:19
08/22/19
08/22
07:19
08/22/19
07:19
Recommendations
Target analyst commentary  »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

MSG

Madison Square Garden

$260.99

-6.38 (-2.39%)

07:19
08/22/19
08/22
07:19
08/22/19
07:19
Initiation
Madison Square Garden initiated  »

Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$108.00

9.96 (10.16%)

07:16
08/22/19
08/22
07:16
08/22/19
07:16
Recommendations
Lowe's analyst commentary  »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 20

    Nov

COO

Cooper Companies

$332.66

0.39 (0.12%)

, ESLOY

EssilorLuxottica

$0.00

(0.00%)

07:12
08/22/19
08/22
07:12
08/22/19
07:12
Recommendations
Cooper Companies, EssilorLuxottica analyst commentary  »

Cooper Companies price…

COO

Cooper Companies

$332.66

0.39 (0.12%)

ESLOY

EssilorLuxottica

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 04

    Sep

CERN

Cerner

$71.77

0.44 (0.62%)

07:12
08/22/19
08/22
07:12
08/22/19
07:12
Upgrade
Cerner rating change  »

Cerner upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 09

    Sep

TGT

Target

$103.11

17.54 (20.50%)

07:12
08/22/19
08/22
07:12
08/22/19
07:12
Recommendations
Target analyst commentary  »

Target price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

SLM

Sallie Mae

$8.29

0.07 (0.85%)

07:11
08/22/19
08/22
07:11
08/22/19
07:11
Recommendations
Sallie Mae analyst commentary  »

Sallie Mae added to US…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

ORBC

Orbcomm

$4.84

-0.055 (-1.12%)

07:10
08/22/19
08/22
07:10
08/22/19
07:10
Upgrade
Orbcomm rating change  »

Orbcomm upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSD

Clearside Biomedical

$1.27

0.09 (7.66%)

07:10
08/22/19
08/22
07:10
08/22/19
07:10
Hot Stocks
Clearside Biomedical plans to resubmit XIPERE NDA in 1Q20 »

Clearside Biomedical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

RCKT

Rocket Pharmaceuticals

$11.44

0.115 (1.02%)

07:09
08/22/19
08/22
07:09
08/22/19
07:09
Hot Stocks
Rocket Pharmaceuticals announces clearance to commence Phase 2 FANCOLEN-II trial »

Rocket Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

HIW

Highwoods Properties

$43.92

0.14 (0.32%)

07:09
08/22/19
08/22
07:09
08/22/19
07:09
Conference/Events
Highwoods Properties to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

MYGN

Myriad Genetics

$25.12

0.67 (2.74%)

07:08
08/22/19
08/22
07:08
08/22/19
07:08
Hot Stocks
Myriad 'applauds' USPSTF recommendation on BRCA-related cancer prevention »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 13

    Nov

KSHB

KushCo Holdings

$0.00

(0.00%)

07:08
08/22/19
08/22
07:08
08/22/19
07:08
Hot Stocks
KushCo Holdings secures $50M credit facility from Monroe Capital »

KushCo Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTRX

Retrophin

$17.39

0.3 (1.76%)

07:07
08/22/19
08/22
07:07
08/22/19
07:07
Hot Stocks
Breaking Hot Stocks news story on Retrophin »

Retrophin down 25% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRAX

Social Reality

$3.39

-0.06 (-1.74%)

07:06
08/22/19
08/22
07:06
08/22/19
07:06
Hot Stocks
Social Reality changing name to SRAX August 26th »

SRAX will formally change…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLHF

Standard Lithium

$0.00

(0.00%)

07:05
08/22/19
08/22
07:05
08/22/19
07:05
Hot Stocks
Standard Lithium completes fabrication of Phase 1, 2 of 'LiSTR' plant »

Standard Lithium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.